In this study, we have shown that SLC1A5, which is a primary transporter for Gln uptake, is highly expressed in a subset of ER + tumours that have high proliferation, i.e., luminal B tumours, and is related to poor patient outcome in this group. Here, SLC1A5 is linked to neoplasm.